RedHill Biopharma Ltd. (RDHL) shareholders
Close on Nov 17, 2026Market cap $1.78MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| SC-Sigma Global Partners, LP Joint filing with YA II PN, Ltd. (9.90%), YA Global Investments II (U.S.), LP (9.90%) and 5 more | 508,723 | 9.90% | 13G (passive) | Dec 19, 2025 |
| Alumni Capital LP Joint filing with Alumni Capital GP LLC (9.99%), Ashkan Mapar (9.99%) | 369,373 | 9.99% | 13G (passive) | Jun 20, 2025 |
| Hal Mintz | – | – | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RDHL | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Yorkville Advisors Global, LP | 122,131 | 0.00% | $106.68K | −228,739 | 0.12% |
| Gagnon Securities LLC | 88,405 | 0.00% | $74.70K | – | 0.01% |
| Citadel Advisors LLC | 65,321 | 0.00% | $55.20K | +44,648 | 0.00% |
| Rhumbline Advisers | 13,755 | 0.00% | $11.62K | +8,639 | 0.00% |
| Lido Advisors, LLC | 11,009 | 0.00% | $9.30K | New | 0.00% |
| GAMMA Investing LLC | 6,957 | 0.00% | $5.88K | +273 | 0.00% |
| Citigroup Inc | 4,378 | 0.00% | $3.70K | New | 0.00% |
| Federation des caisses Desjardins du Quebec | 3,388 | 0.00% | $2.86K | – | 0.00% |
| Royal Bank of Canada | 351 | 0.00% | $0 | +350 | 0.00% |
| UBS Group AG | 100 | 0.00% | $85 | −726 | 0.00% |
| SBI Securities Co., Ltd. | 15 | 0.00% | $13 | +11 | 0.00% |
| Smartleaf Asset Management LLC | 5 | 0.00% | $4 | – | 0.00% |
| Vermillion Wealth Management, Inc. | 2 | 0.00% | $2 | – | 0.00% |
| Morgan Stanley | 1 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 14 | 0M | 0.0% | 2 / 5 | 2 / 4 | 0M | 0M |
| Q1 2026 | 16 | 1M | 0.0% | 3 / 5 | 1 / 4 | 0M | 0M |
| Q4 2025 | 17 | 0M | 0.0% | 4 / 3 | 3 / 1 | 0M | 0M |
| Q3 2025 | 14 | 0M | 0.0% | 4 / 0 | 5 / 2 | 0M | 0M |
| Q2 2025 | 12 | 0M | 0.0% | 1 / 5 | 3 / 1 | 0M | 0M |
| Q1 2025 | 12 | 0M | 0.0% | 2 / 3 | 3 / 1 | 0M | 0M |
| Q4 2024 | 11 | 0M | 0.0% | 3 / 4 | 1 / 3 | 0M | 0M |
| Q3 2024 | 11 | 0M | 0.0% | 3 / 3 | 5 / 10 | 0M | 0M |
| Q2 2024 | 18 | 0M | 0.0% | 3 / 5 | 5 / 2 | 0M | 0M |
| Q1 2024 | 17 | 0M | 0.0% | 3 / 6 | 1 / 5 | 0M | 0M |
| Q4 2023 | 19 | 0M | 0.0% | 5 / 6 | 1 / 5 | 0M | 0M |
| Q3 2023 | 19 | 0M | 0.0% | 3 / 5 | 4 / 4 | 0M | 0M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Dror Ben-Asher | Chief Executive Officer, Director | 441,350,000 | 0.87% | Mar 18, 2026 |
| Rick D. Scruggs | Chief Commercial Officer, Director | 312,500,000 | 0.61% | Mar 18, 2026 |
| Gilead Raday | Chief Operating Officer | 176,910,000 | 0.35% | Oct 6, 2026 |
| Adi Frish | Chief Corp & BD Officer | 276,810,000 | 0.54% | Mar 18, 2026 |
| Guy Joel Goldberg | Chief Business Officer | 305,720,000 | 0.60% | Mar 18, 2026 |
| Razi Ingber | Chief Financial Officer | 277,560,000 | 0.55% | Mar 18, 2026 |
| Ofer Tsimchi | Director | 146,250,000 | 0.29% | Mar 19, 2026 |
| Kenneth Reed | Director | 105,200,000 | 0.21% | Mar 18, 2026 |
| Shmuel Cabilly | Director | 105,200,000 | 0.21% | Mar 18, 2026 |
| Roni Mamluk | Director | 103,500,000 | 0.20% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Gilead Raday Chief Operating Officer | Oct 1, 2026 | Sale | −14,310,000 | $0.00 | $1.43K | 176,910,000 |
| Gilead Raday Chief Operating Officer | Jul 10, 2026 | Sale | −14,130,000 | – | – | 218,780,000 |
| Gilead Raday Chief Operating Officer | Apr 6, 2026 | Sale | −15,740,000 | – | – | 261,060,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of RedHill Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 736,481 shares on Sep 1, 2026 over the last 90 days.
See a number that looks wrong?